WO1990008819A1 - Vaccine for the preventative treatment of infection of liver fluke in ruminants - Google Patents
Vaccine for the preventative treatment of infection of liver fluke in ruminants Download PDFInfo
- Publication number
- WO1990008819A1 WO1990008819A1 PCT/AU1990/000027 AU9000027W WO9008819A1 WO 1990008819 A1 WO1990008819 A1 WO 1990008819A1 AU 9000027 W AU9000027 W AU 9000027W WO 9008819 A1 WO9008819 A1 WO 9008819A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gst
- vaccine
- hepatica
- antigen
- sheep
- Prior art date
Links
- 241000242711 Fasciola hepatica Species 0.000 title claims abstract description 89
- 229960005486 vaccine Drugs 0.000 title claims abstract description 33
- 208000006275 fascioliasis Diseases 0.000 title claims abstract description 22
- 241000282849 Ruminantia Species 0.000 title claims abstract description 15
- 208000015181 infectious disease Diseases 0.000 title abstract description 29
- 108010070675 Glutathione transferase Proteins 0.000 claims abstract description 128
- 102000005720 Glutathione transferase Human genes 0.000 claims abstract description 125
- 239000000427 antigen Substances 0.000 claims abstract description 25
- 108091007433 antigens Proteins 0.000 claims abstract description 25
- 102000036639 antigens Human genes 0.000 claims abstract description 25
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract 5
- 241001494479 Pecora Species 0.000 claims description 68
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 229920000936 Agarose Polymers 0.000 claims description 12
- 241000242678 Schistosoma Species 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 8
- 238000001042 affinity chromatography Methods 0.000 claims description 6
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 102000053602 DNA Human genes 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 4
- 230000003302 anti-idiotype Effects 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 19
- 241001465754 Metazoa Species 0.000 description 48
- 239000002299 complementary DNA Substances 0.000 description 25
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 24
- 150000001413 amino acids Chemical group 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 244000045947 parasite Species 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 238000002255 vaccination Methods 0.000 description 15
- 239000000499 gel Substances 0.000 description 14
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 229960003180 glutathione Drugs 0.000 description 12
- 101000906005 Fasciola hepatica Glutathione S-transferase class-mu 26 kDa isozyme 1 Proteins 0.000 description 11
- 102100036534 Glutathione S-transferase Mu 1 Human genes 0.000 description 11
- 101000851788 Homo sapiens Eukaryotic peptide chain release factor GTP-binding subunit ERF3A Proteins 0.000 description 11
- 101001071694 Homo sapiens Glutathione S-transferase Mu 1 Proteins 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 235000013601 eggs Nutrition 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 241000242680 Schistosoma mansoni Species 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 108010024636 Glutathione Proteins 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 241000935974 Paralichthys dentatus Species 0.000 description 7
- 241000242677 Schistosoma japonicum Species 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000000013 bile duct Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000242541 Trematoda Species 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000000366 juvenile effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000869417 Trematodes Species 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 101100512223 Caenorhabditis elegans gst-42 gene Proteins 0.000 description 3
- 101100338003 Caenorhabditis elegans gst-7 gene Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101000906008 Fasciola hepatica Glutathione S-transferase class-mu 26 kDa isozyme 7 Proteins 0.000 description 3
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 3
- 230000008004 immune attack Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 241000415078 Anemone hepatica Species 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 101100069663 Caenorhabditis elegans gst-1 gene Proteins 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101001068428 Fasciola hepatica Glutathione S-transferase class-mu 26 kDa isozyme 47 Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100037478 Glutathione S-transferase A2 Human genes 0.000 description 2
- 101001026115 Homo sapiens Glutathione S-transferase A2 Proteins 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101100449761 Musca domestica Gst1 gene Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000244154 Taenia ovis Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- PCDWFBFHIIKIPM-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-2-sulfonic acid Chemical compound C1=CC=C2N(CC)C(S(O)(=O)=O)SC2=C1 PCDWFBFHIIKIPM-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100034193 Aspartate aminotransferase, mitochondrial Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000007900 DNA-DNA hybridization Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 101150066516 GST gene Proteins 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- NZYCYASKVWSANA-UHFFFAOYSA-M new methylene blue Chemical compound [Cl-].CCNC1=C(C)C=C2N=C(C=C(C(NCC)=C3)C)C3=[S+]C2=C1 NZYCYASKVWSANA-UHFFFAOYSA-M 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(I) nitrate Inorganic materials [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
- C12N9/1088—Glutathione transferase (2.5.1.18)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to vaccines for the preventative treatment for infection of liver fluke in ruminant animals.
- the invention also relates to methods for the preventative treatment for infection of liver fluke in ruminant animals.
- Fascioliasis Effective control of infection with liver fluke (Fascioliasis) is a major worldwide problem in the animal industry. Fascioliasis is caused by infection with the trematode parasite Fasciola hepatica (F. hepatica). In particular, in ruminants such as sheep and cattle, it can cause serious economic losses due to wasting, death and reduced wool and milk production [1]. Current control methods rely heavily on the use of anthelmintic chemicals but these methods are not always effective [2].
- GST glutathione-S- transferase
- EC 2.5.1.18 are a family of multifunctional proteins involved in the metabolism of a broad range of xenobiotics and the binding and possible transport of endogenous anionic compounds such as bilirubin and heme [9].
- electrophilic substrates are neutralised following conjugation with glutathione, rendering the product water soluble and facilitating excretion.
- US Patent Specification 4743446 (National Research Development Corp) describes antigens specific to the juvenile stage of F. hepatica which are prepared by raising an antiserum against the juvenile flukes, absorbing this antiserum with antigens extracted from adult flukes, separating the immunoglobulins (Ig) from the unabsorbed antiserum and using these Ig to affinity purify juvenile-specific antigens (JSA) from lysates of juvenile fluke.
- JSA juvenile-specific antigens
- European Patent Specification 11438 (Vaccines International Ltd) describes a vaccine against bovine fascioliasis comprising irradiated metacercariae of F. ⁇ i ⁇ antica. The use of irradiated metacercariae for vaccination of sheep a ⁇ ainst F. hepatica has been reported to be unsuccessful [12].
- the present invention provides in one form a vaccine for the preventative treatment for infection of liver fluke in ruminants, the vaccine comprising glutathione-S-transferase (GST) derived from adult worms of F. hepatica.
- GST glutathione-S-transferase
- a vaccine containing GST is able to stimulate immunity in sheep to infection with metacercariae of F. hepatica.
- the GST proteins are purified from adult worms of F. hepatica by affinity chromatography on glutathione-agarose.
- the GST proteins purified by glutathione-agarose chromatography comprise a mixture of proteins of similar molecular weight of about 26,000 and 26,500 Da. These proteins can be fractionated by two dimensional SDS-PAGE into about 10-11 individual components with different apparent pi values.
- the GST used in the present invention may be extracted as described above or alternatively the parts of the molecule responsible for this vaccination effect may be synthesised as peptide molecules or by means of genetic engineering. It will be appreciated that a protective immune response can be achieved by vaccination with a peptide fragment of the GST described. Anti-idiotype antibodies corresponding to the vaccinating epitopes of the GST molecule may also be used as a vaccine.
- Fasciola ⁇ i ⁇ antica which is believed to be the predominant cause of liver fluke infection in tropical zones.
- the vaccine further comprises adjuvants.
- adjuvants Any adjuvants commonly used in similar vaccines may be used but non-oil based adjuvants such as of the aluminium hydroxide type are preferred.
- the vaccine further comprises molecules derived from members of the Fasciola genus or other parasites. It is likely that other molecules, unrelated to GST, may also induce a protective immune response in ruminants and that a cocktail vaccine comprising these other molecules together with GST may be an effective vaccine.
- Figure 1 One dimensional SDS-PAGE analysis of the glutathione-binding molecules purified from a crude homogenate of F. hepatica adult worms by affinity chromatography on glutathione agarose. The position of the molecular weight markers is indicated (in kDa).
- FIG. 3 Comparison of the N-terminal sequences obtained for GSTs of F. hepatica (Fh) to the N-termini of GSTs of other helminths (Schistoceohalus solidus (Ss), Schistosoma mansoni (Sm), Schistosoma japonicum (Sj) and mammalian Mu class GSTs. Homologous regions are boxed. Rat (Rn), mouse (Mm); bovine (Bi) and human (Hs) GSTs are also represented. The bracketed residues indicate uncertain amino acid assignments.
- FIG. 4 Comparison of the sequence of tryptic and chymotryptic peptides of the GSTs of F. hepatica to homologous regions in GSTs of S. mansoni (Sm26), S. japonicum (Sj26) and the mouse (Mm GST1).
- CT18.3 chymotryptic peptide of F. hepatica: T0.7a, T0.7b, T16.3a, T16.3b, T16.2a, T16.2b: tryptic peptides of
- FIG. 6 EUSA analysis of native F. hepatica GST probed with antisera from sheep immunized with GST in Freund's adjuvant (A), infected with F. hepatica for 12 wks (•), infected with F. hepatica for 6 wks ( a ) and normal sheep serum (*).
- FIG. 7 Western blot analysis of native F. hepatica GST probed with antisera from different sheep.
- Panel A an amido black stain of the native protein
- panel B normal sheep serum
- panel C sera from sheep immunized with GST in Freund's adjuvant
- panel D sera from sheep infected with F. heoatica for 6 weeks
- panel E sera from sheep infected with F. hepatica for 12 weeks.
- Sera were used at a dilution of 1/100 (lane 1), 1/300 (lane 2) or 1/1000 flane 3). The position of the molecular weight markers is indicated (kDa).
- Panel A shows the average RBC hemoglobin levels over 36 weeks of infection with F. hepatica in uninfected control sheep ( ), infected control sheep
- Panel B shows average RBC hemoglobin levels in sheep over 36 weeks of infection in uninfected control sheep ( ), infected control sheep ( — ), GST group 1 vaccinated sheep
- Panel A shows the average aspartate aminotransferase serum levels over 36 weeks of infection with F. hepatica in serum from uninfected control sheep ( ), infected control sheep ( — ) and GST-vaccinated sheep ( ).
- Panel B shows average aspartate aminotransferase serum levels in sheep over
- Panel A shows the average L - gamma glutamyltransferase levels over 36 weeks of infection with F. hepatica in uninfected control sheep ( ), infected control sheep (- - -) and GST-vaccinated sheep ( ).
- Panel B shows average
- Panel A shows the average fecal egg counts over 36 weeks of infection with hepatica in infected control sheep (- - -) and GST-vaccinated sheep ( ).
- Figure 15 DNA sequence of the GST 7 cDNA.
- Figure 17. DNA sequence of the GST 47 cDNA.
- Figure 18. DNA sequence of the GST 50 cDNA.
- FIG. 19 Comparison of the amino acid sequences of cloned GST sequences and GST peptides of F. hepatica.
- Sm26 Mr 26,000 GST of S. mansoni: Sj26: Mr 26,000 GST of S. jaoonicumr Fh26a, Fh26b: N-terminal amino acid sequences of GSTs of F. hepatica;
- GST1 ,7,42,47,50 amino acid sequences predicted from the cloned GST cDNAs of F. hepatica. T.05, TO.7b/0.6, T21.5: tryptic peptides of F. hepatica: CT18.3:chymotryptic peptide of F. hepatica.
- the sequences have been aligned to maximise the homology. Dashes indicate unassigned residues.
- Fasciola hepatica adult worms used for purification of GSTs were collected from the livers of sheep slaughtered and processed at local abattoirs in Melbourne. The parasites were transported on ice, washed twice in phosphate buffered saline (PBS) and homogenized in TNET buffer (0.5% v/vTriton X-100 (Triton X-100 is a non-ionic detergent supplied by Rohm & Haas), 10mM EDTA, 0.15M NaCI, in 50mM Tris (pH 7.8) supplemented with 2mM phenyimethylsulphonyi fluoride) ata ratio of 1 ml /worm.
- PBS phosphate buffered saline
- TNET buffer 0.5% v/vTriton X-100
- Triton X-100 is a non-ionic detergent supplied by Rohm & Haas
- 10mM EDTA 0.15M NaCI
- 50mM Tris
- GST ⁇ soenzymes were purified by affinity binding to glutathione (GSH) agarose (Sigma, St Louis, USA). Briefly, TNET Iysates of adult worms were passed down a GSH agarose column, and the matrix washed with several volumes of PBS, prior to elution with a GSH containing buffer (1.5mg/ml GSH in 50mM Tris (pH 9.3) ) [7]. Fractions shown to contain protein were pooled, dialysed against PBS or distilled water and stored at -70°C. The GST content and purity were assessed by Coomassie blue and silver staining of SDS-PAGE gels. Generation of Peptides
- the chymotrypsin digest was prepared by addition of 200 ⁇ l 0.1 M NH 4 HC0 3 , pH 7.8, (C0 2 ) and 10/tg chymotrypsin (Worthington) and proteoiysis conducted at 37°C for 4 hours. Digestion was arrested by storage at -20°C.
- the void volume and peptide peaks suspect of heterogeneous content were refractionated on a Pep PRC 5/5 C 2 /C 18 reverse phase column (Pharmacia) most often using a 0-60% v/v AcN gradient in 0.1% v/v trifluoracetic acid. The elution was monitored at 214nm. Collected peptide peaks were stored at -20°C, and dried by vacuum centrifugation (Savant instruments, Hicksville, USA) prior to amino acid analysis.
- N-terminal and peptide sequencing was conducted at the Department of Veterinary Preclinical Sciences, University of Melbourne, using an ABI Model 471 A Protein Sequencer. Derivitized amino acids were resolved on a 25cm Zorbax PTH column (Dupont) (at 38°C) using isocratic delivery of the resolving buffer (5.529% v/v tetrahydrofuran, 30.17% v/v AcN,
- sample buffer (62.5 mM Tris-HCI containing 3% SDS, 50 mM dithiothreitol a ⁇ d 10% glycerol, pH 6.8), and electrophoresed under reducing conditions on 13% acrylamide slab gels [13].
- Relative molecular weights (M r ) were calculated with reference to protein molecular weight standards (Biorad, Richmond, USA).
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose paper was performed according to the method of Bumette [16], with a transfer time of 18 hours at 15 volts.
- the nitrocellulose sheet was blocked with 5 % skim milk powder in PBS for 3 hours at room temperature.
- the antiserum was diluted 1 in 100 in PBS, added to the nitrocellulose sheet, and incubated for 1 hour.
- the sheet was washed three times in PBS containing 0.1 % Tween 20.
- Affinity-purified rabbit anti-sheep immunogiobulin (Biorad) or goat anti-rabbit immunoglobulin (Kinkegaard and Perry Labs, Gaithersburg, USA) was diluted 1 in 300 in PBS and added to the sheet and incubated at room temperature for 1 hour.
- the sheet was washed 3 times in PBS / 0.1 % Tween 20 (Tween 20 is a non-ionic detergent) and developed using 4 ml of a 3 mg/ml solution of 4-chloro-1-napthol (Sigma) in cold methanol mixed with 20 ml PBS containing 12 ⁇ l of hydrogen peroxide.
- the location of the transferred protein was established by staining in a solution of 0.004 % amido black in 45 % methanol / 10 % acetic acid. lodination of proteins
- the native GSTs of F. hepatica were radioiodinated using the Boiton and Hunter procedure [17].
- Polyvinyl microtitre plates were coated overnight at 4-C with 50 ⁇ l purified GST (5 ⁇ g/ml) in 0.1 M sodium carbonate buffer (pH 9.5). Sera were diluted in EUSA buffer (0.1 M Tris HO, 0.5 M NaCI, 2 mM EDTA, 0.05 % Tween 20, 0.05 mM thiomersal, pH 8.0) supplemented with 0.2 % bovine serum albumin, and 50 ⁇ l of the appropriate dilution was incubated in the microtiter plate for 1 hour at 37° C. The wells were washed 3 times between incubations with PBS containing 0.1% v/v Tween 20.
- Affinity-purified rabbit anti-sheep immunoglobulin conjugated to horse radish peroxidase was diluted in EUSA buffer, 50 ⁇ l was added to each well and incubated for 1 hour at 37° C.
- the substrate 1 mM 2,2-Azinobis (3-ethylbenzthiazole sulphonic acid) (ABTS) in 0.062 M citric acid / 0.076 M Na 2 HP0 4 pH 4.0, 0.03 % hydrogen peroxide, was added to each well. After 1 hour, the optical density at 414 nm was measured with an automated Titertek Multiskan spectrophotometer.
- a group of 10 sheep were immunized by subcutaneous injection of 10Q ⁇ g of purified GST of F. hepatica in Freund's complete adjuvant (FCA) 16 weeks prior to infection followed by a boost with 100 ⁇ g of purified GST in Freund's incomplete adjuvant (IFA) 12 weeks prior to infection.
- FCA hepatica in Freund's complete adjuvant
- IFA Freund's incomplete adjuvant
- the sheep were given subsequent boosts of 100 ⁇ g of purified GST in PBS at approximatly 4 week intervals throughout the 52 weeks of the trial.
- a group of 10 control sheep were treated identically, with PBS substituted for the GST antigen.
- a group of 8 sheep were not immunized.
- Serum taken at each time interval was assayed for the liver enzymes aspartate aminotransferase (EC 2.6.1.1.) (AST) [19] and L-gamma glutamyltransferase (EC 2.3.2.2.) (GGT) [20] and red blood cell (RBC) hemoglobin [21] on a Roche Cobas MIRA automatic analyser (Basel, Switzerland). Serum was stored frozen at -20*C until use.
- AST aspartate aminotransferase
- GTT L-gamma glutamyltransferase
- RBC red blood cell
- Fecal egg counts were performed by the method of Kelly et al [22] with the following changes.
- One gram of feces was suspended in 9ml of water and passed through a sieve into a tapered urine flask to remove coarse fecal material.
- the eggs were allowed to settle for 6 minutes and most of the supematent removed. This procedure was repeated once and yielded about 10 ml of sediment containing F. hepatica eggs.
- Several drops of 0.1 % new methylene blue were added to the final sediment to a volume of 10 ml and poured into a square lined petri dish. The number of eggs/g feces were counted under a dissecting microscope.
- RNA was extracted from adult worms of the Compton strain of F. hepatica by the method of Chirgwin et al [24]. Poly(A) + RNA was selected by oligo dT chromatography [25]. The cDNA libraries were constructed in phage vectors gtl 1 a ⁇ dfcAP by CLONTECH (Palo Alto, USA) using the procedure of Gubler and Hoffman [26].
- the cDNA libraries were screened for expression of GSTs of F. hepatica using the Protoblot method as described in the Protoblot Technical Manual purchased from PROMEGA (Madison, USA). The library was screened with a rabbit antiserum raised to the purified GSTs of F. hepatica at a dilution of 1/600. Filters were blocked in a buffer containing
- Antibodies in the rabbit anti-GST serum were depleted of specificities to sequences expressed in the GST1 clone before the ⁇ ZAP library was rescreened to identify other GSTs of F. hepatica.
- Undiluted rabbit antiserum (1ml) was incubated with 1ml of a sonicate of E. coli expressing ⁇ -galactosidase for 16 hours at 4°C to deplete anti- E. coli specificities.
- This depleted serum was diluted to 1/600 with PBS and 10m! of this serum was incubated on a filter to which an induced confluent lawn of clone GST1 had been absorbed. After 1 hour at room temperature, the serum was removed and used to screen the/ZAP library.
- One positive plaque was obtained (termed GST 7) which was rescreened to purity.
- Radiolabelled probes were prepared as described by using the BRL (Gaithersburg, USA) nick translation kit as recommended by the supplier.
- Phagemid DNA containing cDNA inserts from positive ⁇ ZAP phage clones was isolated by excision in vivo of the pBluescript phagemid under the conditions recommended by Stratagene (La Jolla, USA). Phagemid DNA was extracted by the method of Birnboim and Doly [27]. Double-stranded DNA sequencing of cDNA inserts was performed by the chain termination method [28].
- the GST fraction comprises protein extracted from a population of individual adult worms isolated from several infected sheep livers. Since each sheep could be infected with several strains of F. hepatica which may exhibit sequence polymorphisms within GST isoenzymes, the multiple protein components observed within our GST fraction could represent allelic variants of one or a few GST isoenzymes within the polymorphic fluke population studied. Alternatively, each component could be the product of an individual GST gene within a clonal fluke population. Amino acid sequence of native GSTs of F. hepatica
- N terminal amino acid sequences of the purified F. hepatica GSTs revealed two different but related sequences. Comparison of these sequences (Fh26a, Fh26b) with the corresponding regions of Schistosoma [7,30,31] and known mammalian GSTs [31,37] showed very high levels of homology (Fig. 3). Conservation of several key regions of sequence resulted in identities of 52-76% and 55-77% for Fh26a and Fh26b respectively (Table 1).
- T21.5b and T21.6a are identical and show 69% identity with the Oterminal region of the M r 26,000 GST of S. japonicum and S. mansoni.
- the RBC hemoglobin levels in the uninfected control animals remained consistently high around a mean of 12 g/L over the period of the trial.
- the GST vaccinated sheep displayed levels consistently orientated around the median between the uninfected and the infected control animals (Fig 8a).
- Fig 8b When the GST vaccinated animals were analysed further as two sub-populations (Fig 8b), based solely upon relative RBC haemoglobin levels through the trial, it was found that 4 of the animals (GST group 1) displayed consistently higher levels of RBC hemoglobin than the infected controls, while the remaining 5 animals (GST group 2) demonstrated a decrease with time, consistent with the infected controls.
- AST serum levels were analysed to assess the level of liver parenchymal damage in the trial animals.
- the GST-vaccinated animals consistently displayed levels of serum AST similar to the infected control animals (Fig 9a).
- the GST-vaccinated animals were assessed as 2 sub-populations (Fig 9b)
- the GST group 1 animals displayed lower serum levels over the initial 10 weeks with a slightly delayed maximum reached at week 6 compared to week 4 in the infected control animals.
- the animals in GST group 2 did not display any differences in AST serum levels from the infected control animals.
- GGT levels in serum are an indicator of damage to the liver and specifically the bile ducts and were analysed to monitor damage resulting from the establishment of parasites in the bile ducts.
- the level of GGT in the GST-vaccinated animals demonstrated a profile similar to that recorded for the infected control animals (Fig 10a) with a rise in the levels of enzyme in serum detectable by week 2, peak values by week 12 and a slow decrease after this time. No comparable release of GGT into serum was detected in the uninfected control animals.
- GST-vaccinated animals were analysed as sub-populations (Fig 10b)
- GST group 1 displayed lower GGT levels over the initial 12 weeks and with maximal levels not attained until week 14.
- GGT levels in the GST group 2 again coincided with the infected controls. This suggests that the GST group 1 subpopulation of animals have a decreased and delayed onset of liver damage compared with the controls and the GST group 2 subpopulation.
- the sheep were slaughtered over a period of 13 weeks (weeks 44 - wk 57), post infection, and the worm burdens within each liver were ascertained ( Figure 12 and Table 2).
- the 10 infected controls sacrificed to date, contained an average of 241 parasites in comparison to the GST-vaccinated animals with a mean of 107 parasites representing an overall reduction in worm burden of 55 % (p ⁇ 0.001).
- the GST group 1 group exhibited a mean worm count of 54, representing a reduction of 77% (p ⁇ 0.001)
- the GST group 2 group exhibited a mean worm count of 149, representing a reduction of 38% (p ⁇ 0.025).
- one third of the GST-vaccinated animals exhibited worm burdens of less than 15 % of the mean burden in the control animals.
- Rabbit antiserum was raised to the purified GST fraction by subcutaneous injection of F. hepatica GST in Freund's adjuvant. This antiserum identifies various GST species of M p 26,000 and 26,500 on Western blots of the purified GST fraction separated by two dimensional SDS-PAGE (Fig 13). This antiserum was used to isolate cDNA sequences of
- GST1 and GST7 Two cDNA clones (termed GST1 and GST7) were identified.
- the cDNA sequence of GST7 was used to isolate other homologous cDNA sequences in the library by DNA-DNA hybridization which identified 3 other cDNA sequences (termed GST42, GST47 and GST50).
- the amino acid sequences predicted by each of the cDNA sequences is shown in Fig 19 together with an alignment with the M r 26,000 GST sequences of Schistosoma [7,30].
- Each cDNA sequence predicts a single open reading frame.
- the GST 1 amino acid sequence begins 22 amino acids from the N terminus of GST peptides (Fh26b) and shows a degree of homology with this sequence.
- the GST 7 amino acid sequence begins 7 amino acids from the N terminus of GST (Fh26a) and is identical to this sequence.
- the GST47 amino acid sequence begins 6 amino acids from the N terminus of GST (Fh 26a, b) and shows high homology with these sequences.
- the GST42 and GST50 sequences are much shorter.
- the GSTs of adult worms of F. hepatica comprise two major components of approximate M 26,000 and 26,500 which can be further fractionated into 10-11 components by two dimensional SDS-PAGE.
- Direct sequencing of the GST fraction of F. hepatica identified two major N-terminal sequences.
- peptides derived from internal or C-termi ⁇ al regions of GSTs were identified by homology with other known GSTs. From these data, it is evident that the glutathione binding molecules purified do represent the GSTs of hepatica.
- the isolation and sequencing of near identical peptides indicates the high degree of heterogeneity in the F. hepatica GST fraction and implies the expression of multiple GST genes in this parasite.
- the health of the animals and the progression of the infection was monitored by the assay of several biochemical parameters in erythrocytes and serum.
- a subpopulation of the GST vaccinated animals (GST group 1) displayed a clear biochemical pattern consistent with both a reduced worm burden as well as a delay in the establishment of these worms in the bile ducts.
- the subsequent finding of a 77 % reduction (p ⁇ 0.001 ) in worm burden in these animals was complementary to the biochemical findings.
- a statistically significant reduction (p ⁇ 0.025) in worm burden of 38 % was also demonstrated in the GST group 2.
- An overall reduction in worm burden of 55 % (p ⁇ 0.001) was demonstrated in the vaccinated group as a whole.
- the nature of the protective immune response directed against the parasite remains uncertain.
- a strong humoral response to GST of F. hepatica has been induced in all the vaccinated animals but the members of GST group 1 do not exhibit a differentially higher antibody titre relative to the GST group 2 animals. It is therefore uncertain if a humoral response and/or a T-cell response is necessary to induce the protective effect observed.
- the target of the immune attack could be GST in the metacercariae and/or in the newly excysted juvenile resulting in the subsequent damage and elimination of the parasite.lt is also possible that immune attack on the GST of F. hepatica has facilitated induction of a response to a novel parasite antigen leading to the death of the parasite.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2502498A JPH04507235A (en) | 1989-01-31 | 1990-01-31 | Vaccines for prophylactic treatment against liver fluke infections in ruminants |
AU50283/90A AU634754B2 (en) | 1989-01-31 | 1990-01-31 | Vaccine for the preventative treatment of infection of liver fluke in ruminants |
BR909007070A BR9007070A (en) | 1989-01-31 | 1990-01-31 | VACCINE FOR THE PREVENTIVE TREATMENT OF INFECTION BY TREMATOID WORKS OF THE LIVER IN RUMINANTS |
NO91912942A NO912942L (en) | 1989-01-31 | 1991-07-29 | VACCINE FOR PREVENTIVE TREATMENT OF INFECTION OF LIVERABILITY OF DRUGS. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPJ2481 | 1989-01-31 | ||
AUPJ248189 | 1989-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990008819A1 true WO1990008819A1 (en) | 1990-08-09 |
Family
ID=3773671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1990/000027 WO1990008819A1 (en) | 1989-01-31 | 1990-01-31 | Vaccine for the preventative treatment of infection of liver fluke in ruminants |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0456662A4 (en) |
JP (1) | JPH04507235A (en) |
AU (1) | AU634754B2 (en) |
BR (1) | BR9007070A (en) |
CA (1) | CA2045663A1 (en) |
NO (1) | NO912942L (en) |
NZ (1) | NZ232327A (en) |
WO (1) | WO1990008819A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992003735A1 (en) * | 1990-08-20 | 1992-03-05 | British Technology Group Ltd | Liver fluke diagnostic system |
WO1994009142A1 (en) * | 1992-10-21 | 1994-04-28 | Mallinckrodt Veterinary, Inc. | Vaccine containing a thiol protease |
WO1997047740A3 (en) * | 1996-06-11 | 1998-03-26 | Mallinckrodt Veterinary Inc | VACCINE CONTAINING A PEROXIREDOXIN AND/OR A β-TUBULIN |
CN1061991C (en) * | 1994-06-08 | 2001-02-14 | 北京医科大学 | Schistosome vaccine peptide NO.3 |
CN1061990C (en) * | 1994-06-08 | 2001-02-14 | 北京医科大学 | Schistosome vaccine peptide No.1 |
CN1068334C (en) * | 1994-06-08 | 2001-07-11 | 北京医科大学 | Schistosome vaccine peptide No.2 |
CN105903007A (en) * | 2016-06-15 | 2016-08-31 | 青海大学 | Design and preparation method and application of novel fasciola hepatica multi-epitope vaccine |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2657883A1 (en) * | 1990-02-07 | 1991-08-09 | Transgene Sa | |
EP0647138A4 (en) * | 1993-02-05 | 1996-03-06 | Daratech Pty Ltd | Polypeptides obtainable from species of fasciola, and vaccines, methods of treatment and dna sequences of the same. |
CN1132514A (en) * | 1993-09-28 | 1996-10-02 | 墨尔本大学 | Protective antigens against parasites |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5310286A (en) * | 1984-12-21 | 1986-07-22 | National Research Development Corp. | Liver fluke antigens |
AU1793288A (en) * | 1987-05-28 | 1988-12-21 | Millipore Corporation | Novel fusion proteins containing glutathione-s-transferase |
-
1990
- 1990-01-31 AU AU50283/90A patent/AU634754B2/en not_active Ceased
- 1990-01-31 EP EP19900902123 patent/EP0456662A4/en not_active Ceased
- 1990-01-31 BR BR909007070A patent/BR9007070A/en not_active Application Discontinuation
- 1990-01-31 JP JP2502498A patent/JPH04507235A/en active Pending
- 1990-01-31 CA CA002045663A patent/CA2045663A1/en not_active Abandoned
- 1990-01-31 WO PCT/AU1990/000027 patent/WO1990008819A1/en not_active Application Discontinuation
- 1990-01-31 NZ NZ232327A patent/NZ232327A/en unknown
-
1991
- 1991-07-29 NO NO91912942A patent/NO912942L/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5310286A (en) * | 1984-12-21 | 1986-07-22 | National Research Development Corp. | Liver fluke antigens |
AU1793288A (en) * | 1987-05-28 | 1988-12-21 | Millipore Corporation | Novel fusion proteins containing glutathione-s-transferase |
Non-Patent Citations (2)
Title |
---|
HOWELL, M.J. et al, Journal of Parasitology, Volume 74 Number 4, issued August 1988 "Glutathione S-Transferases in Fasciola Hepatica" See pages 715-718. * |
See also references of EP0456662A4 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992003735A1 (en) * | 1990-08-20 | 1992-03-05 | British Technology Group Ltd | Liver fluke diagnostic system |
WO1994009142A1 (en) * | 1992-10-21 | 1994-04-28 | Mallinckrodt Veterinary, Inc. | Vaccine containing a thiol protease |
US6623735B1 (en) * | 1992-10-21 | 2003-09-23 | John P. Dalton | Vaccine containing a thiol protease |
CN1061991C (en) * | 1994-06-08 | 2001-02-14 | 北京医科大学 | Schistosome vaccine peptide NO.3 |
CN1061990C (en) * | 1994-06-08 | 2001-02-14 | 北京医科大学 | Schistosome vaccine peptide No.1 |
CN1068334C (en) * | 1994-06-08 | 2001-07-11 | 北京医科大学 | Schistosome vaccine peptide No.2 |
WO1997047740A3 (en) * | 1996-06-11 | 1998-03-26 | Mallinckrodt Veterinary Inc | VACCINE CONTAINING A PEROXIREDOXIN AND/OR A β-TUBULIN |
AU732807B2 (en) * | 1996-06-11 | 2001-05-03 | John Pius Dalton | Vaccine containing a peroxiredoxin and/or a beta-tubulin |
US6676944B2 (en) | 1996-06-11 | 2004-01-13 | John P. Dalton | Vaccine containing a peroxiredoxin and/or a β-tubulin |
CN105903007A (en) * | 2016-06-15 | 2016-08-31 | 青海大学 | Design and preparation method and application of novel fasciola hepatica multi-epitope vaccine |
Also Published As
Publication number | Publication date |
---|---|
EP0456662A1 (en) | 1991-11-21 |
EP0456662A4 (en) | 1991-12-11 |
CA2045663A1 (en) | 1990-08-01 |
NO912942D0 (en) | 1991-07-29 |
AU5028390A (en) | 1990-08-24 |
AU634754B2 (en) | 1993-03-04 |
JPH04507235A (en) | 1992-12-17 |
NZ232327A (en) | 1993-02-25 |
NO912942L (en) | 1991-09-26 |
BR9007070A (en) | 1991-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Estunningsih et al. | Evaluation of antigens of Fasciola gigantica as vaccines against tropical fasciolosis in cattle | |
Schmitzova et al. | A family of major royal jelly proteins of the honeybee Apis mellifera L. | |
Henkle et al. | Comparison of the cloned genes of the 26-and 28-kilodalton glutathione S-transferases of Schistosoma japonicum and Schistosoma mansoni | |
AU634754B2 (en) | Vaccine for the preventative treatment of infection of liver fluke in ruminants | |
Izacc et al. | Molecular cloning, characterization and expression of the heat shock protein 60 gene from the human pathogenic fungus Paracoccidioides brasiliensis | |
BG62700B1 (en) | Molecules of recombinant desoxyribonucleinic acid (dna) encoding enzymes animopeptase, and their application for the preparation of vaccines against helminth infections | |
Alvarez-Garcia et al. | The NcGRA7 gene encodes the immunodominant 17 kDa antigen of Neospora caninum | |
Smith et al. | Aspartyl proteases from the intestinal brush border of Haemonchus contortus as protective antigens for sheep | |
Witcombe et al. | Molecular characterisation of EmTFP250: a novel member of the TRAP protein family in Eimeria maxima | |
EP0290565B1 (en) | Vaccine containing tick antigens | |
EP0953047B1 (en) | Vaccine containing a peroxiredoxin | |
AU2018201329B2 (en) | Sheep nematode vaccine | |
US5650154A (en) | Protective antigens against disease pathogens | |
US7462707B1 (en) | Nucleic acids encoding a recombinant 250 kDa antigen from sporozoites/merozoites of Eimeria maxima and their uses | |
EP0527977A1 (en) | Nematode vaccine. | |
CA2008808A1 (en) | Vaccine composition | |
US6235283B1 (en) | DNA encoding a cell membrane glycoprotein of a tick gut | |
AU696260B2 (en) | Helminth parasite antigen with aminopeptidase-like activity | |
WO1995009182A1 (en) | Protective antigens against parasites | |
EP1539820B1 (en) | Ostertagia vaccine | |
EP0417524B1 (en) | Antigens and polypeptides derived from babesia (12D3 antigen) | |
JP2002247989A (en) | 14 kDa antigen of Ascarisum-infected larvae, nucleic acid molecules encoding the same, and uses thereof | |
NZ723022B2 (en) | Sheep nematode vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2045663 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990902123 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1990902123 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWR | Wipo information: refused in national office |
Ref document number: 1990902123 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990902123 Country of ref document: EP |